Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Andrea K Miyahira; Robert B Den; Maria I Carlo; Renée de Leeuw; Thomas A Hope; Fatima Karzai; Rana R McKay; Simpa S Salami; Jonathan W Simons; Kenneth J Pienta; Howard R Soule

doi:10.1002/pros.23729

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Prostate. 2019 Feb;79(3):244-258. doi: 10.1002/pros.23729. Epub 2018 Oct 31.

Authors

Andrea K Miyahira¹, Robert B Den², Maria I Carlo³, Renée de Leeuw⁴, Thomas A Hope^{5

6

7}, Fatima Karzai⁸, Rana R McKay⁹, Simpa S Salami^{10

11}, Jonathan W Simons¹, Kenneth J Pienta^{12

13

14}, Howard R Soule¹

Affiliations

¹ Prostate Cancer Foundation, Santa Monica, California.
² Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois.
⁵ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
⁶ Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
⁷ UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
⁸ Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
⁹ Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California.
¹⁰ Department of Urology, University of Michigan Health System, Ann Arbor, Michigan.
¹¹ University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.
¹² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland.
¹³ Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.
¹⁴ Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.

PMID: 30381857
DOI: 10.1002/pros.23729

Abstract

Introduction: The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Tumor Cell Heterogeneity and Resistance," was held in Los Angeles, California from June 21 to 24, 2018.

Methods: The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance.

Results: The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity.

Discussion: This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

Keywords: biomarkers; cancer immunotherapy; molecular imaging; therapeutics; tumor genomics.

Publication types

Review

MeSH terms

Animals
Humans
Male
Molecular Targeted Therapy
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / therapy